tiprankstipranks
TipRanksStock Market NewsCHRS NewsCredit Suisse Thinks Coherus Biosciences’ Stock is Going to Recover
Blurbs

Credit Suisse Thinks Coherus Biosciences’ Stock is Going to Recover

Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Coherus Biosciences (CHRSResearch Report) yesterday and set a price target of $24.50. The company’s shares closed last Thursday at $11.56, close to its 52-week low of $10.53.

According to TipRanks.com, Biasio is a 4-star analyst with an average return of 7.3% and a 60.5% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Merck & Company, and Thermo Fisher.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $24.40 average price target, representing a 107.0% upside. In a report issued on February 17, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.

See the top stocks recommended by analysts >>

Coherus Biosciences’ market cap is currently $900.7M and has a P/E ratio of -3.04.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Read More on CHRS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More